Hospital Acquired Infection Control Market Size & Growth Forecast 2026–2035, By Segments (Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Hospital Acquired Infection Control Market size was around USD 22.03 Billion in 2025 and is slated to grow at a 6.7% CAGR from 2026 to 2035, surpassing USD 42.14 Billion by 2035. The industry revenue for 2026 is calculated at USD 23.32 billion.

• Base Year Value (2025): USD 22.03 Billion
• CAGR (2026-2035): 6.7%
• Forecast Year Value (2035): USD 42.14 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Hospital Acquired Infection Control Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America captured a 51.70% market share in 2025, supported by advanced hospital infrastructure, established infection surveillance, strict compliance standards, and consistent investment in infection prevention solutions.
  • Asia Pacific is forecast to expand at a 7.57% CAGR as hospital infrastructure grows, standardized infection prevention practices increase, and healthcare facilities strengthen hygiene and sterilization protocols.

• Segment Momentum:

  • Hospitals and ICUs lead the market because high-risk patients, invasive procedures, and continuous care require sustained infection prevention measures, driving consistently high demand for infection control solutions.
  • Services are growing fastest as healthcare providers increasingly adopt outsourced sterilization, infection surveillance, training, and compliance support to strengthen infection control without expanding internal operational resources.

• Market Expansion Drivers:

  • Increasing hospital-acquired infection incidence driving urgent prevention and control demand.
  • Advanced sterilization and smart surveillance technologies improving infection control efficiency.
  • Strengthening healthcare compliance standards enforcing stricter infection prevention protocols.

• Industry Adoption Constraints:

• Leading Market Participants:

  Top players in the hospital acquired infection control market include 3M Company (United States), STERIS plc (Ireland), Getinge AB (Sweden), Advanced Sterilization Products, Inc. (United States), Belimed AG (Switzerland), Sotera Health Company (United States), Midmark Corporation (United States), MMM Group (Germany), Owens & Minor, Inc. (United States), W&H Dentalwerk Bürmoos GmbH (Austria).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 22.03 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 42.14 Billion by 2035
  • Growth Forecasts: 6.7% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Consumables (Type) | Hospitals and Intensive Care Units (ICUs) (End Use)
  • Emerging Opportunity Segment: Services (Type) | Ambulatory Surgical and Diagnostic Centres (End Use)

Market Growth Drivers and Industry Trends

Increasing hospital-acquired infection incidence driving urgent prevention and control demand

Rising incidence of hospital-acquired infections is pushing healthcare providers to treat prevention as an operational priority rather than a discretionary quality initiative, directly increasing demand for the hospital acquired infection control market. As infection events increase the likelihood of longer patient stays, readmissions, isolation requirements, and reputational scrutiny, hospitals are expanding purchases of disinfection systems, sterilization equipment, protective consumables, and infection monitoring solutions that can reduce transmission risk in high-contact clinical settings. This trend also changes procurement behavior, with infection control budgets gaining urgency and faster approval cycles, especially for products and services tied to intensive care units, surgical environments, and device-associated infection prevention.

Advanced sterilization and smart surveillance technologies improving infection control efficiency

Technology improvements are supporting market development by making infection control programs more measurable, consistent, and scalable for healthcare facilities. In the hospital acquired infection control market, advanced sterilization systems reduce variability in decontamination workflows, while smart surveillance platforms help infection prevention teams detect emerging transmission patterns, monitor compliance gaps, and intervene earlier in patient care settings. That practical combination of automation and visibility supports adoption because hospitals are not only buying products, but also investing in tools that help staff use resources more efficiently, document performance more clearly, and target infection risks with greater precision.

Strengthening healthcare compliance standards enforcing stricter infection prevention protocols

Tighter healthcare compliance requirements are increasing market penetration by turning infection prevention from a recommended practice into a documented institutional obligation. In the hospital acquired infection control market, stricter protocols lead hospitals to standardize cleaning procedures, upgrade sterilization infrastructure, expand use of validated consumables, and implement tracking systems that can demonstrate adherence during audits and accreditation reviews. Compliance pressure also influences purchasing decisions toward solutions with clearer efficacy data, process traceability, and compatibility with formal hospital infection control policies, reinforcing steady replacement and upgrade activity.

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 51.70% share of the hospital acquired infection control market in 2025, supported by the region’s high concentration of acute care hospitals, established infection surveillance protocols, and routine use of disinfection, sterilization, and monitoring systems across healthcare settings. Leadership is underpinned by strict compliance requirements and consistent hospital spending on infection prevention workflows, which keeps demand active for products and services used to reduce cross-contamination, manage outbreaks, and support patient safety standards in day-to-day clinical operations.

Asia Pacific is projected to expand at a 7.57% CAGR over the forecast period in the hospital acquired infection control market, impelled by the ongoing expansion of hospital infrastructure and the rising adoption of standardized infection prevention practices across developing healthcare systems. Growth is accelerating as more facilities formalize hygiene protocols, increase procurement of sterilization and surface decontamination solutions, and respond to higher patient volumes that make infection control a more operationally critical part of hospital management.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Developing
Cost-Sensitive Region	Low	High	Medium	High	High
Regulatory Environment	Supportive	Neutral	Supportive	Neutral	Neutral
Demand Drivers	Strong	Strong	Moderate	Moderate	Moderate
Development Stage	Developed	Developing	Developed	Developing	Developing
Adoption Rate	High	High	Medium	Medium	Medium
New Entrants / Startups	Dense	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Strong	Stable	Stable	Stable

No card data available for this language/report.

Segment Leadership and Growth Trends

  Type Segment Analysis: Consumables (Largest Segment) vs Services (Fastest-Growing Segment)

Within the hospital acquired infection control market, Consumables held a 49.69% share in 2025, making it the leading type segment. This position is sustained by the routine and recurring use of products such as disinfectants, sterilization supplies, protective items, and other infection prevention materials that hospitals must replenish continuously as part of daily clinical operations. Demand remains closely tied to standard infection control protocols, patient throughput, and compliance requirements, which gives Consumables a stable volume base that service-based alternatives do not match at the same scale.

Services are emerging as the fastest-growing type segment in the hospital acquired infection control market as healthcare providers place greater emphasis on outsourced sterilization support, infection surveillance, training, and compliance management. Growth is being underpinned by the practical need for specialized expertise and standardized execution across increasingly complex care environments, especially where healthcare facilities seek to improve infection outcomes without expanding internal operational burdens. Compared with consumables, services are gaining momentum because they address ongoing process management and institutional capability gaps rather than product replenishment alone.

End Use Segment Analysis: Hospitals and Intensive Care Units (ICUs) (Largest Segment) vs Ambulatory Surgical and Diagnostic Centres (Fastest-Growing Segment)

Hospitals and Intensive Care Units (ICUs) accounted for the largest share of the hospital acquired infection control market in 2025. Their leadership reflects the concentration of high-risk patients, invasive procedures, extended lengths of stay, and continuous exposure to infection-sensitive environments, all of which require strict and sustained infection prevention practices. The intensity of care delivery in these settings keeps consumption of infection control products and protocols consistently high, supporting their dominant share across end use categories.

Ambulatory Surgical and Diagnostic Centres represent the fastest-growing end use segment in the hospital acquired infection control market, driven by the rising need to maintain rigorous infection prevention standards in lower-stay, high-throughput care settings. As more procedures and diagnostic interventions are handled outside traditional inpatient environments, these centres are strengthening sterilization, disinfection, and patient safety processes to align with clinical expectations and regulatory requirements. Their growth is outpacing hospitals because infection control investment is expanding from a smaller base while operational volumes in outpatient settings continue to increase.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Equipment, Services, Consumables	Consumables	Services
End Use	Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centres, Others	Hospitals and Intensive Care Units (ICUs)	Ambulatory Surgical and Diagnostic Centres

Competitive Landscape and Market Positioning

Major players in the hospital acquired infection control market:

1. 3M Company (United States)

2. STERIS plc (Ireland)

3. Getinge AB (Sweden)

4. Advanced Sterilization Products Inc. (United States)

5. Belimed AG (Switzerland)

6. Sotera Health Company (United States)

7. Midmark Corporation (United States)

8. MMM Group (Germany)

9. Owens & Minor Inc. (United States)

10. W&H Dentalwerk Bürmoos GmbH (Austria)

Infection prevention strategies are becoming more advanced through integrated hygiene monitoring and sterilization technologies. Collaborative healthcare initiatives are strengthening the development of more effective infection control protocols. The hospital acquired infection control market is evolving through innovation aimed at reducing contamination risks and improving patient safety outcomes.

Industry Development/News

Company Name	Date	Key Development
Getinge	Jan-25	Getinge acquired Healthmark Industries, expanding its infection control consumables portfolio and reinforcing its distribution capabilities in the U.S. healthcare market. The acquisition strengthens Getinge’s positioning in sterile processing solutions by integrating complementary product lines used in hospital infection prevention workflows, supporting broader coverage across central sterile supply departments.
Midmark Corporation	Jul-24	Midmark Corporation launched its next-generation M11 and M9 steam sterilizers featuring enhanced durability, usability, and integrated instrument processing and compliance documentation functions. The introduction strengthens hospital sterilization workflows by improving operational efficiency and traceability in infection control processes within clinical and surgical environments.
MMM Group	Jun-23	MMM Group partnered with Southwest Clinic to establish a centralized CSSD/RUMED facility at the Calw clinic site in Germany. The facility consolidates reprocessing of critical medical instruments for multiple clinics, improving sterilization efficiency, compliance control, and centralized infection prevention infrastructure across regional healthcare operations.
Sterigenics U.S., LLC	May-22	Sterigenics U.S., LLC expanded its electron beam (E-beam) sterilization facility in Indiana, increasing capacity for medical and pharmaceutical product sterilization. The expansion strengthens global infection prevention supply chains by enhancing throughput for outsourced sterilization services critical to healthcare and life sciences manufacturing.